Autor(es): Johnson Barbara W, Goodman Christin H, Holloway Kimberly, de Salazar P Martinez, Valadere Anne M, Drebot Mike

Resumo: Commercial chikungunya virus (CHIKV)-specific IgM detection kits were evaluated at the Centers for Disease Control - Prevention (CDC), the Public Health Agency of Canada National Microbiology Laboratory, - the Caribbean Public Health Agency (CARPHA). The Euroimmun Anti-CHIKV IgM ELISA kit had ? 95% concordance with all three reference laboratory results. The limit of detection for low CHIK IgM+ samples, as measured by serial dilution of seven sera up to 1:12,800 ranged from 1:800 to 1:3,200. The Euroimmun IIFT kit evaluated at CDC - CARPHA performed well, but required more retesting of equivocal results. The InBios CHIKjj Detect MAC-ELISA had 100% - 98% concordance with CDC - CARPHA results, respectively, - had equal sensitivity to the CDC MAC-ELISA to 1:12,800 dilution in serially diluted samples. The Abcam Anti-CHIKV IgM ELISA initially had high performance at CDC - CARPHA, but at CDC, performance was inconsistent between lots. After replacement of the biotinylated IgM antibody controls with serum containing CHIKV-specific IgM - additional quality assurance/control measures, the Abcam kit was rereleased - reevaluated at CDC. The reformatted Abcam kit had 97% concordance with CDC results - limit of detection of 1:800 to 1:3,200. Two rapid tests - three other CHIKV MAC-ELISAs evaluated at CDC had low sensitivity, as the CDC CHIKV IgM in-house positive controls were below the level of detection. In conclusion, laboratories have options for CHIKV serological diagnosis using validated commercial kits.

Imprenta: The American Journal of Tropical Medicine and Hygiene, v. 95, n. 1, p. 182-192, 2016

Identificador do objeto digital: 10.4269/ajtmh.16-0013

Descritores: Chikungunya virus - Viral infections ; Chikungunya virus - Serological diagnosis ; Chikungunya Virus - Virus ; Chikungunya virus - Public health

Data de publicação: 2016

INDICADORES

ACESSO